Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 9Recruiting 8Active not recruiting 4Unknown 3Terminated 2Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 86Thoracic 28Gastrointestinal 21Dermatologic 19Gynecologic 18Head & Neck 17Breast 13Other solid neoplasm 5Lymphoid 3CNS 3Sarcoma 2Myeloid 1

Conditions

Sarcoma 172Glioblastoma 72Gliosarcoma 70Brain Neoplasms 41Osteosarcoma 40Neoplasms 40Astrocytoma 38Recurrence 35Melanoma 33Oligodendroglioma 32Gastrointestinal Stromal Tumors 31Breast Neoplasms 31Glioma 30Lymphoma 29Dendritic Cell Sarcoma, Interdigitating 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Neoplasm Metastasis 28Central Nervous System Neoplasms 27Burkitt Lymphoma 26Bone Neoplasms 26Ovarian Neoplasms 25Colorectal Neoplasms 24Neuroblastoma 22Lymphoma, Non-Hodgkin 22Lymphoma, Large B-Cell, Diffuse 22Stomach Neoplasms 21Sarcoma, Ewing 21Lung Neoplasms 19Leukemia, Myeloid, Acute 19Leukemia 19

Interventions

temsirolimus 1avelumab 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Transitional Cell × Sarcoma × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT04260802 2026-01-12

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Ocellaris Pharma, Inc.

Phase 1/2 Terminated
73 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡